The primary treatment for estrogen receptor positive (ER+), HER2− BC are therapies targeting estrogen signaling; however, resistance to these therapies in metastatic BC (mBC) and disease progression remains a significant challenge (Osborne and Schiff, 2011). Here, ESR1 is linked to breast cancer.